Prothena Corp. (PRTA) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
May 3, 2016 4:06 PM EDTNet cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programsInitiated PRONTO, a registration-directed, global Phase 2b trial of NEOD001 in patients with AL amyloidosisInitiated Phase 1b multiple ascending dose, proof-of-biology study of PRX003 in patients with psoriasisAppointed experienced biotechnology executive David B. McNinch as Chief Commercial Officer... More
